A pilot trial targeting the icos-icos-l pathway in nonhuman primate kidney transplantation

American Journal of Transplantation

Volumn 15, Issue 4, 2015, Pages 984-992

  Lo, D J ^a   Anderson, D J ^a   Song, M ^a   Leopardi, F ^b   Farris, A B ^a   Strobert, E ^c   Chapin, S ^d   Devens, B ^d   Karrer, E ^d   Kirk, A D ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d Perseid Therapeutics   (United States)

Author keywords

animal models: nonhuman primate; costimulation; immunosuppression immune modulation; kidney transplantation nephrology; translational research science

Indexed keywords

BELATACEPT; CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; HLA B7 ANTIGEN; HYBRID PROTEIN; INDUCIBLE T CELL COSTIMULATOR; INDUCIBLE T CELL COSTIMULATOR LIGAND; INDUCIBLE T CELL COSTIMULATOR LIGAND IMMUNOGLOBULIN FUSION PROTEIN; UNCLASSIFIED DRUG; ABATACEPT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFECT; GRAFT SURVIVAL; IMMUNOHISTOCHEMISTRY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; MEMORY T LYMPHOCYTE; MONOTHERAPY; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REJECTION FREE SURVIVAL; RHESUS MONKEY; ANIMAL; GRAFT REJECTION; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOPHENOTYPING; METABOLISM; T LYMPHOCYTE;

ABATACEPT; ANIMALS; GRAFT REJECTION; IMMUNOLOGIC MEMORY; IMMUNOPHENOTYPING; INDUCIBLE T-CELL CO-STIMULATOR PROTEIN; KIDNEY TRANSPLANTATION; MACACA MULATTA; PILOT PROJECTS; T-LYMPHOCYTES;

EID: 84925296544     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.13100     Document Type: Article

References (35)

1. Rostaing L, Vincenti F, Grinyo J, et al. Long-term belatacept exposure maintains efficacy and safety at 5 years: Results from the long-term extension of the BENEFIT study. Am J Transplant 2013; 13: 2875-2883.
2. Vanrenterghem Y, Bresnahan B, Campistol J, et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation 2011; 91: 976-983.
3. Vincenti F, Charpentier B, Vanrenterghem Y, et al. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study). Am J Transplant 2010; 10: 535-546.
4. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397: 263-266.
5. Yoshinaga SK, Whoriskey JS, Khare SD, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402: 827-832.
6. Aicher A, Hayden-Ledbetter M, Brady WA, et al. Characterization of human inducible costimulator ligand expression and function. J Immunol 2000; 164: 4689-4696.
7. Swallow MM, Wallin JJ, Sha WC., B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha. Immunity 1999; 11: 423-432.
8. Coyle AJ, Lehar S, Lloyd C, et al. The CD28-related molecule ICOS is required for effective T cell-dependent immune responses. Immunity 2000; 13: 95-105.
9. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical for CD40-mediated antibody class switching. Nature 2001; 409: 102-105.
10. Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses. Nature 2001; 409: 105-109.
11. Ozkaynak E, Gao W, Shemmeri N, et al. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection. Nat Immunol 2001; 2: 591-596.
12. Azimzadeh AM, Pfeiffer S, Wu G, et al. Alloimmunity in primate heart recipients with CD154 blockade: Evidence for alternative costimulation mechanisms. Transplantation 2006; 81: 255-264.
13. Nanji SA, Hancock WW, Anderson CC, et al. Multiple combination therapies involving blockade of ICOS/B7RP-1 costimulation facilitate long-term islet allograft survival. Am J Transplant 2004; 4: 526-536.
14. Akalin E, Dikman S, Murphy B, Bromberg JS, Hancock WW., Glomerular infiltration by CXCR3+ ICOS+ activated T cells in chronic allograft nephropathy with transplant glomerulopathy. Am J Transplant 2003; 3: 1116-1120.
15. Schenk AD, Nozaki T, Rabant M, Valujskikh A, Fairchild RL., Donor-reactive CD8 memory T cells infiltrate cardiac allografts within 24-h posttransplant in naive recipients. Am J Transplant 2008; 8: 1652-1661.
16. Schenk AD, Gorbacheva V, Rabant M, Fairchild RL, Valujskikh A., Effector functions of donor-reactive CD8 memory T cells are dependent on ICOS induced during division in cardiac grafts. Am J Transplant 2009; 9: 64-73.
17. Kosuge H, Suzuki J, Gotoh R, et al. Induction of immunologic tolerance to cardiac allograft by simultaneous blockade of inducible co-stimulator and cytotoxic T-lymphocyte antigen 4 pathway. Transplantation 2003; 75: 1374-1379.
18. Zhang QW, Rabant M, Schenk A, Valujskikh A., ICOS-dependent and -independent functions of memory CD4 T cells in allograft rejection. Am J Transplant 2008; 8: 497-506.
19. Harada H, Salama AD, Sho M, et al. The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J Clin Invest 2003; 112: 234-243.
20. Salama AD, Yuan X, Nayer A, et al. Interaction between ICOS-B7RP1 and B7-CD28 costimulatory pathways in alloimmune responses in vivo. Am J Transplant 2003; 3: 390-395.
21. Kashizuka H, Sho M, Nomi T, et al. Role of the ICOS-B7h costimulatory pathway in the pathophysiology of chronic allograft rejection. Transplantation 2005; 79: 1045-1050.
22. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci USA 1997; 94: 8789-8794.
23. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723.
24. Pitcher CJ, Hagen SI, Walker JM, et al. Development and homeostasis of T cell memory in rhesus macaque. J Immunol 2002; 168: 29-43.
25. Lo DJ, Weaver TA, Stempora L, et al. Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. Am J Transplant 2011; 11: 22-33.
26. Chalasani G, Dai Z, Konieczny BT, Baddoura FK, Lakkis FG., Recall and propagation of allospecific memory T cells independent of secondary lymphoid organs. Proc Natl Acad Sci USA 2002; 99: 6175-6180.
27. Dengler TJ, Pober JS., Human vascular endothelial cells stimulate memory but not naive CD8+ T cells to differentiate into CTL retaining an early activation phenotype. J Immunol 2000; 164: 5146-5155.
28. Rottman JB, Smith T, Tonra JR, et al. The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. Nat Immunol 2001; 2: 605-611.
29. Sperling AI, Bluestone JA., ICOS costimulation: It's not just for TH2 cells anymore. Nat Immunol 2001; 2: 573-574.
30. Burmeister Y, Lischke T, Dahler AC, et al. ICOS controls the pool size of effector-memory and regulatory T cells. J Immunol 2008; 180: 774-782.
31. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8: 1024-1032.
32. Zheng J, Chan PL, Liu Y, et al. ICOS regulates the generation and function of human CD4+ Treg in a CTLA-4 dependent manner. PLoS One 2013; 8: e82203.
33. Lo DJ, Anderson DJ, Weaver TA, et al. Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. Am J Transplant 2013; 13: 320-328.
34. Liu D, Krummey SM, Badell IR, et al. 2B4 (CD244) induced by selective CD28 blockade functionally regulates allograft-specific CD8+ T cell responses. J Exp Med 2014; 211: 297-311.
35. Habicht A, Najafian N, Yagita H, Sayegh MH, Clarkson MR., New insights in CD28-independent allograft rejection. Am J Transplant 2007; 7: 1917-1926.